louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05589012: Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
Official title: Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Zika Virus Infection
Keywords: trophoblast
placenta
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2022-10-21
Enrollment: 8
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women

Brief summary: Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate

Detailed description: The analysis will relate for each virus studied + control + favipiravir to 1 placenta in the 1st trimester and 1 placenta at term.

2 experiments per virus will be planned.

Eligibility criteria: Inclusion Criteria:

* Patient over 18 years old
* Singleton pregnancy of normal course, at term, birth by caesarean section OR
* Trophoblast from Voluntary Termination of Pregnancy (IVG), after endo-uterine aspiration

Exclusion Criteria:

* Need for pathological, genetic or bacteriological examination of the placenta
* Multiple pregnancy
* HBV+ (Hepatitis B positive), HCV+ (Hepatitis C positive) , known CMV seroconversion during pregnancy (CytoMégaloVirus)
* Immunosuppression (drugs, corticosteroids, etc.)
* Diabetes
* Pre eclampsia
* Intrauterine growth retardation (IUGR),
* Vascular or placental pathology.
* Refusal to participate
* Patient under guardianship / curatorship / security measure
* Patient under AME (state medical aid)

Primary outcomes:
measure: To assess the replication potential of TONV and ZIKV after placenta infection ex vivo.
timeFrame: inclusion
Secondary outcomes:
measure: Validate the ex vivo placental model for TONV.
timeFrame: Inclusion
measure: Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).
timeFrame: first trimester
measure: Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).
timeFrame: first trimester
measure: Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).
timeFrame: first trimester
measure: Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).
timeFrame: term
measure: Compare the placental infection of TONV versus ZIKV.
timeFrame: inclusion
measure: Compare the placental infection of TONV versus ZIKV.
timeFrame: inclusion
measure: Compare the placental infection of TONV versus ZIKV.
timeFrame: inclusion
measure: Highlight the cellular targets of TONV.
timeFrame: inclusion
measure: Highlight the cellular targets of TONV.
timeFrame: inclusion
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04779112: Detecting Acetabulum Movement After Total Hip Arthroplasty From Serial Plain Radiographs
Official title: Detecting Acetabulum Movement After Total Hip Arthroplasty From Serial Plain Radiographs
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Orthopedics
Lead sponsor: Taipei Medical University
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of hospital

Brief summary: This study mainly measures the orientation of acetabulum cup post total hip arthroplasty. Using "Liaw's Version", a new and accurate standardization method, investigators are trying to analyze acetabulum cup anterversion change postoperatively.

Detailed description: Patients undergoing total hip arthroplasty have generally good prognosis. However, clinically there was still a minority of patients who suffered from persistent postoperative pain. Dislocations of hip leading to revision surgeries were as well observed in some patients.

This study mainly measures the orientation of acetabulum cup post total hip arthroplasty. Using "Liaw's Version", a new and accurate standardization method, investigators are trying to analyze acetabulum cup anterversion change postoperatively.

As previously known, the anteversion of acetabulum cup determines the range of motion, stability, and the function after total hip arthroplasty. Cup malalignment increase impingement, dislocation, cup migration, and polyethylene wear. Finding a pattern may help the early diagnosis of acetabular loosening.

Eligibility criteria: Inclusion Criteria:

* Patients undergone total hip arthroplasty
* Patients undergone total hip arthroplasty with more than two postoperative X-ray plain films

Exclusion Criteria:

* Patients with postoperative periprosthetic fracture(s)
* Patients with postoperative infection
* Patients undergone revision total hip arthroplasty

Primary outcomes:
measure: Analyze acetabulum cup anterversion change postoperatively
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Taipei Medical University
name: Chen-Kun Liaw
role: STUDY_CHAIR
References:
Clinical trial NCT00242112: Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI
Official title: Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2005-10-19
Enrollment: 31
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine the ability of functional MRI techniques to detect, measure and locate intra-prostatic cancer.

Detailed description: The purpose of this study is to determine the ability of functional MRI techniques \[High Resolution Dynamic Contrast Enhanced MRI (HR-DCE-MRI), diffusion weighted MRI (DWI) and BOLD MRI\] to detect, measure and locate intra-prostatic cancer. 70 patients undergoing MRI for staging of prostate cancer prior to radical prostatectomy will be studied. Results of MRI obtained prior to surgery will be correlated with pathologic specimens to determine MRI accuracy.

Eligibility criteria: Patients will be recruited from the University Health Network (UHN). Eligible patients will be undergoing radical prostatectomy for prostate cancer at UHN. Patients with a contraindication to MRI or MRI contrast agents, claustrophobia, renal failure, allergy to MRI contrast agents, or prior hormonal therapy or radiation therapy for prostate cancer, a biopsy within 3 weeks of the surgical date or active prostatitis will be excluded.

Primary outcomes:
measure: Extent and Grade of Prostate Cancer Using MRI
timeFrame: Imaging followed by pathology analysis
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network, Princess Margaret Hospital
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Masoom Haider, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03152812: Functional Outcome of Free Muscle Flaps Versus Free Skin Flaps for Post-traumatic Foot Plantar Surface Reconstruction
Official title: Functional Outcome of Free Muscle Flaps Versus Free Skin Flaps for Post-traumatic Foot Plantar Surface Reconstruction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Best Tissue Constituent for Plantar Surface
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-15
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: any individual having post traumatic soft tissue defect of plantar surface requiring free flap reconstruction regardless to age

Brief summary: the investigators are trying to detect what is the best tissue constituent suitable for reconstruction of large post traumatic sof tissue defects of foot plantar surface


Eligibility criteria: Inclusion Criteria:

1. Posttraumatic large soft tissue defects of plantar surface requiring free tissue transfer for coverage
2. At any age

Exclusion Criteria:

1-defects that can be managed by local flaps 2-Non traumatic soft tissue defects

-

Primary outcomes:
measure: Time to mobilize
timeFrame: 2 years
measure: Requirement of specialized Footwear
timeFrame: 2 years
Secondary outcomes:
measure: flap ulceration
timeFrame: 2 years
measure: Shear forces across the flap
timeFrame: 2 years
Other outcomes:
Locations:
city: Assuit
country: Egypt
facility: Assiut University
state: Assiut
Study officials:
affiliation: Assiut University
name: Amr El-Said Ali Ibrahim, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04598412: Comparison of Dietary Protein Intake Patterns and Inadequate Protein Intake in Older Adults Among Countries
Official title: Comparison of Dietary Protein Intake Patterns and Inadequate Protein Intake in Older Adults Among Countries
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Keywords: Protein intake
Older adults
Lead sponsor: Centro Universitario de Ciencias de la Salud, Mexico
Sponsor class: OTHER
Collaborators: name: Hospital General de Occidente
First posted: 2020-10-22
Enrollment: 522
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community dwelling older adults (\>60 y) from different countries.

Brief summary: The researchers will compare protein intake patterns per day and per meal among older adults from different countries. The analysis will also compare the proportion of inadequate protein intake per day (different cut points), per meal (breakfast, lunch, dinner), and the number of meals per day that reach an adequate protein content.

Detailed description: There will be a literature review in search of other studies reporting protein intake patterns in older adults. These studies must report total, and per-meal protein intake, evaluated through 24-h dietary recalls, food diaries or food frequency questionnaires. Afterwards, the researchers will contact the authors for data requests and analyze the data; these data will also include some demographic variables (e.g. sex, age, height, weight). Once the data are obtained, the patterns of protein intake will be compared among countries with an ANOVA test. As it is very likely that variances and/or sample sizes will be unequal, a Welch's correction and a Dunnett test for post hoc analyses will be performed. This analysis is going to be performed for the whole sample and by sex. Similarly, the proportion of older adults that do not reach the recommended amounts of protein in a daily (0.8, 1.0, 1.2 g/kg/day) and per meal basis (30 g, 0.4 g/kg) will be calculated. These proportions will be compared among countries with a chi-squared test and employing a z-test for proportions (with Bonferroni adjustment) to identify pairwise differences.

Eligibility criteria: Inclusion Criteria:

* Community dwelling

Exclusion Criteria:

* Incomplete data registries

Primary outcomes:
measure: Inadequate protein intake per day
timeFrame: One day
measure: Inadequate protein intake per meal
timeFrame: One day
measure: Meals per day with adequate protein content
timeFrame: One day
Secondary outcomes:
Other outcomes:
Locations:
city: Guadalajara
country: Mexico
facility: Instituto de Ciencias Aplicadas a la Actividad Física y al Deporte
state: Jalisco
Study officials:
affiliation: University of Guadalajara
name: Alejandro Gaytán-González
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06567912: The Development of the Simulation Curriculum and AI-incorporated Assessment Tool for Transesophageal Echocardiography
Official title: The Development of the Simulation Curriculum and Artificial Intelligence-incorporated Assessment Tools for Transesophageal Echocardiography in Patients With Cardiac Arrest
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Out-Of-Hospital Cardiac Arrest
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2024-08-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: emergency physicians

Brief summary: This study aims to establish a novel transesophageal echocardiography (TEE) simulation curriculum based on previous research results and suggestions from the American College of Emergency Physicians. To better evaluate the efficacy of the curriculum, an evaluation model utilizing artificial intelligence (AI) would be introduced. The study population is at least 60 junior physicians in the emergency department or other departments interested in TEE. After the curriculum, junior physicians could utilize TEE on cardiac arrest patients and improve diagnostic accuracy and patient outcomes.

Detailed description: This study aims to establish a novel TEE simulation curriculum based on previous research results and suggestions from the American College of Emergency Physicians. To better evaluate the efficacy of the curriculum, an evaluation model utilizing artificial intelligence (AI) would be introduced. The study population is at least 60 junior physicians in the emergency department or other departments interested in TEE. After the curriculum, junior physicians could utilize TEE on cardiac arrest patients and improve diagnostic accuracy and patient outcomes.

Eligibility criteria: Inclusion Criteria:

Emergency physicians interested in TEE learning.

Exclusion Criteria:

Emergency physicians are not interested in TEE learning.

Primary outcomes:
measure: learning outcomes:immediate assessment
timeFrame: 4 hours
measure: learning outcomes: 3-month evaluation
timeFrame: 3 months
measure: the efficiency of AI model
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Lien
Study officials:
References:
Clinical trial NCT03043612: Ureteral Stent Study
Official title: Cook Ureteral Stent Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Urolithiasis
Keywords: Ureteroscopy for urolithiasis
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2017-02-06
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The purpose of this study is to evaluate the feasibility of the Cook Ureteral Stent to reduce post-stent placement pain and urinary symptoms in patients following ureteroscopy for urolithiasis.


Eligibility criteria: Inclusion Criteria:

* Patient is undergoing ureteroscopy for urolithiasis in which temporary ureteral stenting is indicated

Exclusion Criteria:

* Patient is unwilling or unable to sign and date the informed consent
* Patient is unwilling to comply with the follow-up study schedule
* Patient is pregnant, breast-feeding, or planning to become pregnant during the course of the study
* Patient is currently taking anti-cholinergic or other anti-spasm medications
* Patient is currently taking sildenafil, tadalafil, or vardenafil
* Patient has a known sensitivity to alpha-blocker medications
* Patient is currently undergoing chemotherapy or radiation therapy
* Patient has an active urinary tract infection
* Patient is in chronic renal failure, on hemodialysis, or on chronic peritoneal dialysis
* Patient requires bilateral shock wave lithotripsy, bilateral stents, or has bilateral symptomatic kidney stones
* Patient has had a ureteral stent within the past three months in either ureter
* Patient is unable to accurately detect or report bladder function or pain
* Patient has chronic pain

Primary outcomes:
measure: Patient-reported body pain score
timeFrame: 7-days post stent placement
Secondary outcomes:
Other outcomes:
Locations:
city: Sha Tin
country: Hong Kong
facility: Prince of Wales/Chinese University of Hong Kong
Study officials:
affiliation: Prince of Wales Hospital
name: Chi-Fai Ng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04525612: 68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
Official title: 68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Tumor
Positron-Emission Tomography
Metastasis
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2020-08-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To evaluate the potential usefulness of 68Ga-BNU-PSMA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.

Detailed description: Subjects with various types of cancer underwent 68Ga-BNU-PSMA PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga-BNU-PSMA PET/CT were calculated.

Eligibility criteria: Inclusion Criteria:

* (i) adult population (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled 68Ga-BNU-PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee; (v) healthy volunteers(aged 18 years or order).

Exclusion Criteria:

* (i) patients with pregnancy; (ii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Primary outcomes:
measure: Standardized uptake value (SUV)
timeFrame: 30 days
Secondary outcomes:
measure: Diagnostic efficacy
timeFrame: 30 days
measure: Diagnostic efficacy
timeFrame: 30 days
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: The First Affiliated Hospital of Fujian Medical University
state: Fujian
Study officials:
References:
Clinical trial NCT03614312: Placenta Development Study
Official title: Epigenetic Mechanisms Underlying Trophoblast Syncytialization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2018-08-03
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant

Brief summary: This study will help us learn more about how the placenta develops.

Detailed description: The primary purpose of this study is to understand the epigenetic signaling events in placental trophoblast development.

Eligibility criteria: Inclusion Criteria:

* BMI - 18-25 kg/m2
* at least 18 years of age
* singleton pregnancy
* less than 36 weeks and plan to deliver in the Little Rock/North Little Rock Area

Exclusion Criteria:

* Women with pre-existing medical conditions (e.g. diabetes, hypertension, pre-eclampsia, STD, gestational diabetes)
* Women who are using recreational drugs, tobacco, or alcohol during their pregnancy.
* Women who plan on keeping their placenta following delivery for non-medical reasons.

Primary outcomes:
measure: Number of participants that placental syncytial fusion involves epigenetic changes in histone modifications
timeFrame: 40 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Nutrition Center
state: Arkansas
Study officials:
References:
Clinical trial NCT00003146: Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Official title: A Phase II Trial of Thiotepa, Busulfan, and Melphalan Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Keywords: stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
Lead sponsor: Fred Hutchinson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-04-23
Sex: ALL
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with multiple myeloma.

Detailed description: OBJECTIVES: I. Assess the toxicity and efficacy at the maximum tolerated dose of busulfan, melphalan, and thiotepa in patients with multiple myeloma.

OUTLINE: This is a single arm, open label study. Peripheral blood stem cells (PBSC) are collected and cryopreserved, or bone marrow is harvested and stored, until infusion on day 0. Patients receive oral busulfan every 6 hours on days -8, -7, and -6. Melphalan is administered by continuous IV infusion over 30 minutes on days -5 and -4. Thiotepa is administered by continuous IV infusion over 2 hours on days -3 and -2. Patients undergo PBSC or bone marrow infusion 36-48 hours following the completion of chemotherapy (day 0). Patients are followed for 100 days posttransplant and every 3 months thereafter.

PROJECTED ACCRUAL: 30 patients will be accrued.

Eligibility criteria: DISEASE CHARACTERISTICS: Histologically diagnosed stage II/III multiple myeloma (or have greater than normal beta-2-microglobulin) meeting the Salmon and Durie criteria Stage I multiple myeloma must have had prior chemotherapy before undergoing transplantation

PATIENT CHARACTERISTICS: Age: 70 and under Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL Renal: Creatinine clearance at least 50 mg/min Cardiovascular: Left ventricular ejection fraction at least 41% Other: Not pregnant HIV negative

PRIOR CONCURRENT THERAPY: Not specified

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center
state: Washington
Study officials:
affiliation: Fred Hutchinson Cancer Center
name: William I. Bensinger, MD
role: STUDY_CHAIR
References: